Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quest is a member of a duopoly. As such, it has a strong pricing advantage related to scale.

Quest Diagnostics: A Leader In Its Industry, With COVID Tailwinds Driving Revenue

Quest Diagnostics (DGX) expects the acquisition to broaden the company's spectrum in diagnostic innovation and insights.

Quest Diagnostics (DGX) Acquires Florida-Based NLS Assets

SECAUCUS, N.J., Aug. 17, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Ms.

Quest Diagnostics Elects Tracey C. Doi to Board of Directors

Under the collaboration, eMed's Certified Guide will supervise Quest Diagnostics' (DGX) BinaxNOW home testing process virtually.

Quest Diagnostics (DGX), eMed Deal to Boost BinaxNOW Sales

Telehealth company eMed and Quest Diagnostics Inc (NYSE: DGX) have collaborated for clinician-guided rapid antigen testing for COVID-19 in workplaces. Through the collaboration, the two companies will leverage the BinaxNOW COVID-19 Ag Card Home Test, a self-administered nasal swab antigen test that provides results in 15 minutes.

Quest Diagnostics, eMed Team Up To Offer COVID-19 Rapid Antigen Testing At Workplaces

Quest Diagnostics was the beneficiary of a faster than expected recovery in its base business in the second quarter.

Is This Diagnostics Company a Buy After Blowing Away Earnings Estimates?

Quest Diagnostics CEO Steve Rusckowski told CNBC the company is seeing an increase in Covid-19 tests, with the majority of positive results this week identified as the delta variant.

Quest Diagnostics seeing a rise in Covid tests as delta variant spreads, CEO says

Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2021 Results - Earnings Call Transcript

According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.

Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong

Quest Diagnostics Incorporated (NYSE: DGX) posted better-than-expected second-quarter results, as vaccinations and the lifting of lockdowns resulted in recovery in its core non-coronavirus testing businesses. Q2 adjusted EPS surged almost 125% Y/Y at $3.18, beating the consensus estimate of $2.86.

Quest Q2 Earnings Ahead Of Expectation On Recovery Of Non-COVID Business, Issues Mixed FY21 Guidance

Quest Diagnostics Inc. reported Thursday second-quarter adjusted profit that more than doubled to beat expectations, as revenue also topped forecasts, as the recovery in the lab results and diagnostics company cited a faster-than-expected recovery in its base business. Net income rose to $631 million, or $4.96 a share, from $185 million, or $1.36 a share, in the year-ago period.

Quest Diagnostics adjusted profit more than doubles, beat expectations

SECAUCUS, N.J., July 22, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2021.

Quest Diagnostics Reports Second Quarter 2021 Financial Results; Establishes Full Year 2021 Outlook

Quest Diagnostics (NYSE:DGX) will be releasing its next round of earnings this Thursday, July 22. For all of the relevant information, here is your guide for Thursday's Q2 earnings announcement.

Quest Diagnostics's Earnings: A Preview

Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.

Quest Diagnostics (DGX) Expands Testing Access With CLX Pact

NEWARK, Del., July 20, 2021 /PRNewswire/ -- CLX Health, developer of cloud-based solutions to manage the COVID-19 testing ecosystem with their TrustAssure™ Global Network, today announced a collaboration with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to provide access to COVID-19 molecular diagnostic testing (PCR/NAAT) for people seeking to attend live events nationwide or travel from the United States to destinations around the world.

TrustAssure™ Announces Travel and Live Event Covid Testing through a Collaboration with Quest Diagnostics

Quest Diagnostics' (DGX) second-quarter performance within its non-COVID base business might have registered significant sales rebound.

Base Test Rebound to Drive Quest Diagnostics (DGX) Q2 Earnings

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?

SECAUCUS, N.J., July 14, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2021 Disability Equality Index® (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD).

Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Fourth Consecutive Year

Quest Diagnostics Incorporated (NYSE:DGX) offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, and drugs.

Quest Diagnostics Stock is Worth a Flier Before Earnings

National Vision Hlds

Allscripts Healthcare Solutions

Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.

3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19

TAMPA, Fla., July 12, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services today announced the Tackle Your Testing program to address the health disparities exacerbated by delayed treatment or diagnosis during the COVID-19 pandemic.

Quest Diagnostics and Local Chapters of Feeding America, Big Brothers Big Sisters and Federally Qualified Health Centers Team Up to Address the Hidden Pandemic's Impact on Underserved Communities

Clorox

Cabot Oil & Gas

Gilead Sciences

Hologic

Labcorp Holdings Inc

Merck

Pfizer

PerkinElmer

Regeneron Pharmaceuticals

Texas Instruments

The shares of these S&P 500 companies are not only priced right—they also could hold up better during volatility.

11 Quality Stocks That Are Relatively Cheap

SECAUCUS, N.J., July 6, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2021 financial results on Thursday, July 22, 2021, before the market opens.

Quest Diagnostics To Release Second Quarter 2021 Financial Results On July 22

Arch Capital

Check Point Software Technologies

Markel

Whirlpool

According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have high business predictability ratings and wide margins of safety as of June 30.

5 Guru Stocks With High Business Predictability

Ally Financial

Conagra Brands

Companhia Paranaense de Energia - COPEL

Enel Americas

As of June 29, the GuruFocus All-in-One Screener, a Premium feature, found that the following companies have low price-earnings ratios and high dividend yields.

News for Quest Diagnostics Stock (DGX)